FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2605471103> ?p ?o ?g. }

• W2605471103 endingPage "64" @default.
• W2605471103 startingPage "57" @default.
• W2605471103 abstract "Anti-aminoacyl transfer RNA synthetase antibodies (anti-ARS) are a group of myositis-specific autoantibodies that are detected in the sera of patients with polymyositis and dermatomyositis (PM/DM) and also in those of patients with idiopathic interstitial pneumonias without any connective tissue disease (CTD), including PM/DM. Although we reported the clinical characteristics of interstitial lung disease with anti-ARS antibodies (ARS-ILD) with and without PM/DM, the long-term prognosis of ARS-ILD remains undetermined. As our previous studies revealed that ARS-ILD without PM/DM was similar to CTD-associated ILD, and that ARS-ILD with PM/DM was radiologically suggestive of a nonspecific interstitial pneumonia (NSIP) pathological pattern, we hypothesized that the prognosis of ARS-ILD might be distinct from that of idiopathic pulmonary fibrosis (IPF) without anti-ARS.To elucidate the long-term outcome of ARS-ILD with and without PM/DM and compare it to that of IPF.A two-center retrospective study was conducted. The study population comprised 36 patients with ARS-ILD (8 with PM, 12 with DM, and 16 without myositis throughout the course), 100 patients with IPF without anti-ARS, and 7 patients with NSIP without anti-ARS. The presence of anti-ARS was determined by RNA immunoprecipitation using the sera obtained at the time of diagnosis before specific treatment.During the observational period (median 49 months; range, 1-114 months), 7 patients with ARS-ILD (19%; 3 with PM, 1 with DM, and 3 without PM/DM) and 51 patients with IPF (51%) died. Patients with ARS-ILD had better overall survival than those with IPF (log-rank test, P < 0.001) and similar survival compared to those with NSIP (log-rank test, P = 0.59). The prognosis for patients with ARS-ILD was similar between those with and without myositis (log-rank test, P = 0.91). At the median follow-up time of 76.5 months, 14 of the 36 patients with ARS-ILD had deteriorated. Both a decline in forced vital capacity or an initiation of long-term oxygen therapy during the course (odds ratio [OR], 5.34) and acute exacerbation (OR, 28.4) significantly increased the mortality risk.The long-term outcome of ARS-ILD was significantly better than that of IPF regardless of the presence or absence of myositis." @default.
• W2605471103 created "2017-04-28" @default.
• W2605471103 creator A5000507010 @default.
• W2605471103 creator A5009602385 @default.
• W2605471103 creator A5011674119 @default.
• W2605471103 creator A5015740193 @default.
• W2605471103 creator A5016575106 @default.
• W2605471103 creator A5017927258 @default.
• W2605471103 creator A5020035091 @default.
• W2605471103 creator A5024316557 @default.
• W2605471103 creator A5030428216 @default.
• W2605471103 creator A5042756499 @default.
• W2605471103 creator A5048538074 @default.
• W2605471103 creator A5050554560 @default.
• W2605471103 creator A5052981775 @default.
• W2605471103 creator A5053180213 @default.
• W2605471103 creator A5056631976 @default.
• W2605471103 creator A5061029263 @default.
• W2605471103 creator A5066364417 @default.
• W2605471103 creator A5069197152 @default.
• W2605471103 creator A5078149854 @default.
• W2605471103 creator A5078554949 @default.
• W2605471103 creator A5085556486 @default.
• W2605471103 creator A5086135295 @default.
• W2605471103 date "2017-06-01" @default.
• W2605471103 modified "2023-10-16" @default.
• W2605471103 title "The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies" @default.
• W2605471103 cites W1857071204 @default.
• W2605471103 cites W1910502462 @default.
• W2605471103 cites W1975807940 @default.
• W2605471103 cites W1987213193 @default.
• W2605471103 cites W2000040082 @default.
• W2605471103 cites W2007937936 @default.
• W2605471103 cites W2037262451 @default.
• W2605471103 cites W2039039501 @default.
• W2605471103 cites W2047497161 @default.
• W2605471103 cites W2048716562 @default.
• W2605471103 cites W2049425162 @default.
• W2605471103 cites W2058234974 @default.
• W2605471103 cites W2062006349 @default.
• W2605471103 cites W2065744472 @default.
• W2605471103 cites W2069200039 @default.
• W2605471103 cites W2098305693 @default.
• W2605471103 cites W2102634410 @default.
• W2605471103 cites W2108406461 @default.
• W2605471103 cites W2112877346 @default.
• W2605471103 cites W2117355544 @default.
• W2605471103 cites W2117488044 @default.
• W2605471103 cites W2125078269 @default.
• W2605471103 cites W2134292259 @default.
• W2605471103 cites W2138442131 @default.
• W2605471103 cites W2138871107 @default.
• W2605471103 cites W2149661971 @default.
• W2605471103 cites W2150609695 @default.
• W2605471103 cites W2157869208 @default.
• W2605471103 cites W2166219170 @default.
• W2605471103 cites W2166714841 @default.
• W2605471103 cites W2167383172 @default.
• W2605471103 cites W2168592878 @default.
• W2605471103 cites W2189980859 @default.
• W2605471103 cites W2314311014 @default.
• W2605471103 cites W2341043325 @default.
• W2605471103 cites W2416914730 @default.
• W2605471103 doi "https://doi.org/10.1016/j.rmed.2017.04.007" @default.
• W2605471103 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28461123" @default.
• W2605471103 hasPublicationYear "2017" @default.
• W2605471103 type Work @default.
• W2605471103 sameAs 2605471103 @default.
• W2605471103 citedByCount "33" @default.
• W2605471103 countsByYear W26054711032017 @default.
• W2605471103 countsByYear W26054711032018 @default.
• W2605471103 countsByYear W26054711032019 @default.
• W2605471103 countsByYear W26054711032020 @default.
• W2605471103 countsByYear W26054711032021 @default.
• W2605471103 countsByYear W26054711032022 @default.
• W2605471103 countsByYear W26054711032023 @default.
• W2605471103 crossrefType "journal-article" @default.
• W2605471103 hasAuthorship W2605471103A5000507010 @default.
• W2605471103 hasAuthorship W2605471103A5009602385 @default.
• W2605471103 hasAuthorship W2605471103A5011674119 @default.
• W2605471103 hasAuthorship W2605471103A5015740193 @default.
• W2605471103 hasAuthorship W2605471103A5016575106 @default.
• W2605471103 hasAuthorship W2605471103A5017927258 @default.
• W2605471103 hasAuthorship W2605471103A5020035091 @default.
• W2605471103 hasAuthorship W2605471103A5024316557 @default.
• W2605471103 hasAuthorship W2605471103A5030428216 @default.
• W2605471103 hasAuthorship W2605471103A5042756499 @default.
• W2605471103 hasAuthorship W2605471103A5048538074 @default.
• W2605471103 hasAuthorship W2605471103A5050554560 @default.
• W2605471103 hasAuthorship W2605471103A5052981775 @default.
• W2605471103 hasAuthorship W2605471103A5053180213 @default.
• W2605471103 hasAuthorship W2605471103A5056631976 @default.
• W2605471103 hasAuthorship W2605471103A5061029263 @default.
• W2605471103 hasAuthorship W2605471103A5066364417 @default.
• W2605471103 hasAuthorship W2605471103A5069197152 @default.
• W2605471103 hasAuthorship W2605471103A5078149854 @default.
• W2605471103 hasAuthorship W2605471103A5078554949 @default.
• W2605471103 hasAuthorship W2605471103A5085556486 @default.

• next